<div id="readability-page-1"><p>Vantage Wealth acquired a new stake in  Zoetis Inc. (NYSE:ZTS - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm acquired 108,470 shares of the company's stock, valued at approximately $15,871,000. Zoetis comprises approximately  3.5% of Vantage Wealth's holdings, making the stock its 22nd largest holding.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Norges Bank acquired a new position in  Zoetis during the 2nd quarter valued at about $809,491,000.  Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of  Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company's stock worth $586,671,000 after buying an additional 1,995,491 shares during the last quarter.  Corient Private Wealth LLC lifted its holdings in  Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company's stock valued at $400,619,000 after buying an additional 1,191,840 shares during the period.  Impax Asset Management Group plc boosted its stake in  Zoetis by 362.6% in the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company's stock valued at $182,705,000 after acquiring an additional 922,589 shares during the last quarter.  Finally, Amundi grew its holdings in  Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company's stock worth $575,691,000 after acquiring an additional 846,909 shares during the period. Institutional investors own  92.80% of the company's stock. </p><h2>Zoetis Trading Down 0.3%</h2><p>NYSE:ZTS opened at $122.34 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business's 50-day simple moving average is $128.86 and its 200-day simple moving average is $144.31. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The stock has a market capitalization of $53.91 billion, a PE ratio of 20.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.97. </p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business's quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.  Sell-side analysts expect that  Zoetis Inc. will post 6.07 earnings per share for the current fiscal year. </p><h2>Zoetis Increases Dividend</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This is a boost from Zoetis's previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis's dividend payout ratio  is currently 35.69%. </p><h2>Analysts Set New Price Targets</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>A number of research analysts have recently weighed in on the company. JPMorgan Chase &amp; Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, November 5th. Argus  restated a &#34;buy&#34; rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. UBS Group decreased their target price on Zoetis from $158.00 to $141.00 and set a &#34;neutral&#34; rating for the company in a research report on Wednesday, November 5th. Barclays initiated coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an &#34;equal weight&#34; rating and a $136.00 price target on the stock. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a &#34;buy&#34; rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating and eight have assigned  a Hold rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $160.18.</p><p><b>Check Out Our Latest Stock Report on ZTS</b></p><h2>Zoetis Profile</h2> (Free Report)<p>Zoetis Inc <span>NYSE: ZTS<span></span></span> is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.  </p><p>Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Zoetis</li><li>End of America update</li><li>They Laughed at $30. They Won’t Laugh at $70.</li><li>How Long Will $1M Last in Retirement?</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Vantage Wealth acquired 108,470 shares of Zoetis Inc. (NYSE:ZTS) during Q3, valued at approximately $15.87 million, making it the firm's 22nd largest holding. Other institutional investors also increased their positions in Zoetis. The stock opened at $122.34 on Monday, with a market cap of $53.91 billion. Zoetis reported Q3 earnings of $1.70 per share, beating estimates. The company announced a quarterly dividend increase to $0.53 per share. Analysts have mixed ratings on the stock, with a consensus price target of $160.18.</p>

Vantage Wealth Purchases New Holdings in Zoetis Inc. $ZTS